M A Shipp

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate
    Przemyslaw Juszczynski
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Mol Cell Biol 26:5348-59. 2006
  2. ncbi request reprint Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
    Margaret A Shipp
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 8:68-74. 2002
  3. ncbi request reprint BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration
    R C Aguiar
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 96:4328-34. 2000
  4. ncbi request reprint Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas
    K Takeyama
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Oncogene 27:318-22. 2008
  5. ncbi request reprint Stromelysin-3 suppresses tumor cell apoptosis in a murine model
    E Wu
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Cell Biochem 82:549-55. 2001
  6. ncbi request reprint Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival
    Orion M Howard
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 20:1288-94. 2002
  7. ncbi request reprint FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes
    Hidenobu Takahashi
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3265-71. 2006
  8. ncbi request reprint NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
    Friedrich Feuerhake
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1392-9. 2005
  9. ncbi request reprint High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351
    Bruce A Peterson
    University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Lymphoma 48:870-80. 2007
  10. pmc BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
    Samir Parekh
    Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Blood 110:2067-74. 2007

Research Grants

Collaborators

Detail Information

Publications25

  1. pmc BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate
    Przemyslaw Juszczynski
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Mol Cell Biol 26:5348-59. 2006
    ..IFN-gamma-induced BAL1/BBAP expression contributes to the molecular signature of HR DLBCLs and highlights the interplay between the inflammatory infiltrate and malignant B cells in these tumors...
  2. ncbi request reprint Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
    Margaret A Shipp
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Nat Med 8:68-74. 2002
    ..Our data indicate that supervised learning classification techniques can predict outcome in DLBCL and identify rational targets for intervention...
  3. ncbi request reprint BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration
    R C Aguiar
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 96:4328-34. 2000
    ..Blood. 2000;96:4328-4334)..
  4. ncbi request reprint Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas
    K Takeyama
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Oncogene 27:318-22. 2008
    ..These studies highlight the role of 53BP1 copy loss in primary human DLBCLs and the value of integrative analyses in detecting this genetic lesion in human tumors...
  5. ncbi request reprint Stromelysin-3 suppresses tumor cell apoptosis in a murine model
    E Wu
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Cell Biochem 82:549-55. 2001
    ..Because STR-3 is secreted as an active enzyme rather than a proform, subsequent 45 kDa to 35 kDa STR-3 processing may represent a novel mechanism for regulating enzymatic activity...
  6. ncbi request reprint Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival
    Orion M Howard
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 20:1288-94. 2002
    ..To evaluate the efficacy of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) induction therapy in patients with newly diagnosed mantle-cell lymphoma (MCL)...
  7. ncbi request reprint FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes
    Hidenobu Takahashi
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:3265-71. 2006
    ....
  8. ncbi request reprint NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
    Friedrich Feuerhake
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1392-9. 2005
    ..In this large series of primary MLBCLs and DLBCLs, NFkappaB activation was not associated with amplification of the cREL locus, suggesting alternative pathogenetic mechanisms...
  9. ncbi request reprint High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351
    Bruce A Peterson
    University of Minnesota, Minneapolis, MN 55455, USA
    Leuk Lymphoma 48:870-80. 2007
    ..Six patients have developed AML or MDS. In view of the substantial toxicity accompanying high dose CHOP, the observed outcome suggests that its efficacy is not sufficient to make further study feasible...
  10. pmc BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
    Samir Parekh
    Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Blood 110:2067-74. 2007
    ..Taken together, these results show that BCL6 regulates distinct transcriptional programs through the SMRT/N-CoR and MTA3 corepressors, respectively, and provides a basis for combinatorial therapeutic targeting of BCL6...
  11. ncbi request reprint The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma
    Peter G Smith
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 105:308-16. 2005
    ....
  12. ncbi request reprint The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    Kerry J Savage
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:3871-9. 2003
    ..In almost all cases, c-REL was localized to the nucleus, consistent with activation of the NF-kappa B pathway. These studies identify a molecular link between MLBCL and cHL and a shared survival pathway...
  13. ncbi request reprint The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity
    Kunihiko Takeyama
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Biol Chem 278:21930-7. 2003
    ..Consistent with this idea, BBAP and DTX1 associate via their unique N termini, resulting in enhanced self-ubiquitination...
  14. ncbi request reprint Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
    Stefano Monti
    The Broad Institute, Cambridge, MA, USA
    Blood 105:1851-61. 2005
    ..These studies identify tumor microenvironment and host inflammatory response as defining features in DLBCL and suggest rational treatment targets in specific DLBCL subsets...
  15. ncbi request reprint Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
    Michael J Robertson
    Indiana University Medical Center, Indianapolis, IN, USA
    J Clin Oncol 25:1741-6. 2007
    ..We conducted a multicenter phase II study of a potent inhibitor of PKCbeta, enzastaurin, in patients with relapsed or refractory DLBCL...
  16. ncbi request reprint Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Am J Surg Pathol 31:106-12. 2007
    ..Thus, the combined nuclear localization of c-Rel and the cellular expression of TRAF1 is a highly specific (specificity=98%) means to distinguish PMLBCL from DLBCL that is readily applicable to routine surgical pathology practice...
  17. ncbi request reprint Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
    Scott J Rodig
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:7174-9. 2006
    ..The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed...
  18. ncbi request reprint Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation
    Linfeng Chen
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 108:3428-33. 2006
    ..PTPROt overexpression also inhibited lymphoma cell proliferation and induced apoptosis in the absence of BCR cross-linking, suggesting that the phosphatase modulates tonic BCR signaling...
  19. pmc Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma
    Laura Pasqualucci
    Institute for Cancer Genetics and 2The Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
    J Exp Med 203:311-7. 2006
    ..These findings point to a role for BLIMP1 as a tumor suppressor gene, whose inactivation may contribute to lymphomagenesis by blocking post-GC differentiation of B cells toward plasma cells...
  20. ncbi request reprint Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma
    Hidenobu Takahashi
    Blood 107:844-5. 2006
  21. ncbi request reprint B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity
    Ricardo C T Aguiar
    Division of Hematological Malignancies, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 280:33756-65. 2005
    ..BAL family members are the only described proteins with both PARP and macro domains, underscoring the potential functional significance of this unique combination...
  22. ncbi request reprint Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
    Jeremy S Abramson
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1164-74. 2005
    ..Our increasing molecular understanding of the heterogeneous subsets within DLBCL will likely improve the current empiric therapy of DLBCL by identifying rational therapeutic targets in specific disease subtypes...
  23. ncbi request reprint Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass
    Margaret A Shipp
    Division of Medical Oncology, Dana Farber Cancer Institute, USA
    N Engl J Med 352:1697-704. 2005
  24. ncbi request reprint Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoforms
    Krystel Louis
    INSERM U526, IFR50, Faculté de Médecine Pasteur, 06107 Nice, France
    J Biol Chem 280:1272-83. 2005
    ..Altogether, our data emphasize signaling changes occurring in the tumor microenvironment that may define new stromal targets for therapeutic intervention...
  25. pmc SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma
    Linfeng Chen
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 111:2230-7. 2008
    ..Therefore, SYK-dependent tonic BCR signaling is an important and potentially targetable survival pathway in some, but not all, DLBCLs. In addition, R406-sensitive DLBCLs can be identified by their transcriptional profiles...

Research Grants7

  1. STROMELYSIN 3 AND THE TUMOR MICROENVIRONMENT
    Margaret Shipp; Fiscal Year: 1999
    ....
  2. STROMELYSIN 3 AND THE TUMOR MICROENVIRONMENT
    Margaret Shipp; Fiscal Year: 2000
    ....
  3. STROMELYSIN 3 AND THE TUMOR MICROENVIRONMENT
    Margaret Shipp; Fiscal Year: 2001
    ....
  4. STROMELYSIN 3 AND THE TUMOR MICROENVIRONMENT
    Margaret Shipp; Fiscal Year: 2002
    ....
  5. PROGRAM PROJECT GRANT: Molecular Targets of Germinal Center B-Cell Lymphomas
    Margaret Shipp; Fiscal Year: 2007
    ....